SciBioix Consulting | Application Preview
SciBioix Consulting is seeking government grants to support the development of innovative life-sciences products that utilize microfluidics technology. These products aim to replicate the performance of multi-organ systems, enhancing pharmaceutical and chemical companies' ability to predict responses to drugs and toxins. The company plans to launch a new microfluidics device in the first quarter of 2021, with the goal of having complete human-on-the-benchtop solutions available by 2026.
The business plan addresses the challenges in the biotechnology industry, highlighting the trend of mergers and closures among smaller companies due to rising research and development costs. Despite this, the biotechnology sector is still experiencing growth, with a reduced number of suppliers. SciBioix aims to serve mid-sized biotech companies often overlooked by larger suppliers, capitalizing on the demand for smaller order sizes. By gaining traction with these mid-sized firms, SciBioix can eventually expand its reach to larger pharmaceutical companies.
The rationale for seeking funding stems from the development of all-in-one benchtop solutions that accurately simulate metabolic processes in human organs, such as the lung, liver, and intestine. This is made possible by the proprietary SciBioix™ Cell culture plate, designed to mimic in vivo conditions and enhance predictive pharmacodynamics. The product promises a cost-effective and versatile solution for drug discovery and testing, eliminating the need for significant capital investment.
In a competitive analysis, SciBioix acknowledges the presence of other companies working on micro-models, such as IUVO Microchannel and CellAsic. However, these alternatives often fail to replicate the non-linear nature of compound exposure and the complexities of organ structures. SciBioix distinguishes itself by offering a user-friendly system that provides temporal exposure kinetics without the high setup costs typical of existing devices. This innovative approach positions SciBioix to better meet the needs of researchers and advance the field of in vitro testing while reducing reliance on animal models.
-
General Information
Business Registration Number: 106237989
Location: DURHAM, NC, United States
Length of Operation: 2
Number of Employees:
Annual Gross Income:
Annual Gross Expense:
Open to Loans: NO
-
Funding Usage
SciBioix Innovation develops life-sciences products that replicate the performance of multi-organ systems using microfluidics. Our products will improve pharmaceutical and chemical companies’ ability to predict responses to drugs and toxins. SciBioix Innovation will be launched a new microfluidics device in Q1 2021 with complete human-on-the-benchtop solutions expected to be complete by 2026
-
Business Plan
Over the last five years that have been continuous changes in the biotechnology industry with the United States. The ever-increasing costs to research and develop new drugs have meant continuous mergers, acquisitions, and often closures of smaller companies. Even though there are fewer companies in the market, biotechnology continues to grow, with fewer suppliers than before. The initial opportunity for SciBioix Innovation resides with midsized biotech organizations, those that often work with larger pharmaceutical companies as contract researchers or development partners. Many suppliers focus on the large pharmaceutical companies because of the number of orders, leaving many mid-size companies to struggle to find the needed supplies. SciBioix can be the supplier of cells, tissues, and devices they need to continue to operate. Instead of fewer larger orders, SciBioix can capitalize on many smaller orders. The secondary opportunity for SciBioix Innovation would then be the large pharmaceutical companies that continue to dominate the biotechnology market. As SciBioix Innovation gains traction with mid-sized biotech firms, we can gain the traction and name recognition of the product, and increase our production enough to service both mid-sized researchers and the large biotech firms. SciBioix Innovation is developing a set of all-in-one benchtop solutions that replicate the metabolic processes in the human lung, liver, and intestine to enable in vitro prediction of in vivo metabolic kinetics of chemicals and drugs. The base of these benchtop solutions is our proprietary The SciBioix™ Cell culture plate. The SciBioix plate is a versatile system that is engineered to apply fluidic movement and non-linear drug exposure to in vitro cell culture models. These features of the SciBioix device will enable exposures in an in-vitro model that more realistically simulate in vivo systems. The SciBioix system was designed in keeping with practical cell culture concepts resulting in a ready-to-use, versatile, disposable unit enabling more predictive pharmacodynamics from in vitro models without significant capital investment. SciBioix’s human cell and media products will provide the building blocks to create complete in vitro systems platforms for in vitro drug discovery, efficacy, and toxicity testing.
-
Self Identified Competition
Several groups are developing sophisticated and complex micro-models that combine bioengineering with the functional anatomy of an organ, and they are less likely to provide a realistic means of linking drug or chemical biological effects with actual human pharmacokinetics and pharmacodynamics. One reason for this is the miniature scale, which creates new challenges with regard to assay sensitivity and the balance between tissue mass and fluid volume. The in vitro bio-tool market is currently focused on building relevant tissue technologies and is occupied by IUVO Microchannel, CellAsic, Hurelflow, HepatoPac, and Onyx OrganoPlates. None of these products appropriately model the non-linear nature of compound exposure in human physiology or address compartmental segmentation of complex biological structures to discern key events (KE) of an adverse outcome pathway. Additionally, no existing product provides a cost-effective means for evaluating temporal exposure gradients and parent/metabolite effects amongst diverse cell phenotypes. Development of a physiologically relevant in vitro system grounded in human biology will enable compounds to be more fully evaluated with longer term, multiple exposures, kinetic profiles, with benefits of reduced animal testing. Microfluidic cell culture systems that better recapitulate human physiological conditions are a major area of current innovation. The common goal is to apply fluidics to cell culture which has been shown to improve physiological relevance. Most of the systems that have made it to market use sophisticated pumps, tubes, and valves and require highly trained staff, expensive capital equipment, and entirely unique analysis systems, rendering them too costly and cumbersome for most end-users. Furthermore, the current generation of microfluidic devices are closed systems useful only for imaging-based analysis. Importantly, no other device on the market can accomplish time-resolved exposure kinetics. SciBioix’s device requires no set-up costs, is formatted for compatibility with existing analysis systems, and adds value by including the additional capability to apply kinetic gradients for truly predictive results.
-
Contact Applicant
Subscribe to our Administrator Dashboard to gain full access to this application. Learn More
